Pharmacoeconomics: friend or foe?

被引：20

作者：

Drummond, M. ^{[1
]}

机构：

[1] Univ York, Ctr Hlth Econ, York YO10 5DD, N Yorkshire, England

来源：

ANNALS OF THE RHEUMATIC DISEASES | 2006年 / 65卷

关键词：

D O I：

10.1136/ard.2006.058602

中图分类号：

R5 [内科学];

学科分类号：

1002 [临床医学]; 100201 [内科学];

摘要：

The financial constraints faced by most health systems today make it necessary for manufacturers of new, expensive drugs to demonstrate value for money. This paper describes the different types of economic evaluation; the increasing use of these analysis in decision making; their application to new drugs in the field of in rheumatoid arthritis; and the pros and cons of pharmacoeconomics studies from the perspective of the patients, the physicians, and the general population.

引用

页码：44 / 47

页数：4

共 18 条

[1]

*AC MAN CAR PHARM, 2005, AMCP FORM FORM SUBM

[2]

Using economic evaluations to make formulary coverage decisions - So much for guidelines [J].